摘要
目的探讨非小细胞肺癌患者化疗前后外周血中转化生长因子β1(TGF-β1)水平的变化及其与非小细胞肺癌分期和化疗疗效的关系。方法应用酶联免疫法检测19例非小细胞肺癌化疗前后血清中TGF-β1含量。结果19例非小细胞肺癌患者化疗前TGF-β1浓度显著高于化疗后血清TGF-β1浓度,两者有显著性差异(P<0.05)。Ⅳ期非小细胞肺癌患者血清TGF-β1浓度高于III期非小细胞肺癌患者,两者有显著性差异(P<0.05)。结论TGF-β1在非小细胞肺癌的发生发展中发挥着重要作用,TGF-β1水平可视为非小细胞肺癌患者生存1个独立因素。
Objective To investigate the change of the serum transforming growth factor- β1 （ TGF-β1 ） levels in patients with non-small cell lung cancer before and after chemotherapy. Methods The serum TGF-βlevels were measured by enzymelinked immunoabsorbent assay in 19 NSCLC patients before chemotherapy and after chemotherapy. Results The serum TGF-β1 levels in patients with NSCLC before chemotherapy were significantly higher than that after chemotherapy （ P 〈 0. 05 ）. The serum TGF-β1 levels were significantly higher in patients with stage IV disease compared with that with stage Ⅲ disease （ P 〈 0.05 ）; Conclusion TGF-β1 may play an important role in tumor progression in patients with non-small cell lung cancer. TGF-β1 levels may be an independent predictor of survival in patients with NSCLC.
出处
《实用癌症杂志》
2007年第3期250-251,259,共3页
The Practical Journal of Cancer
关键词
非小细胞肺癌
化疗
转化生长因子Β1
酶联免疫黏附试验
Non-small cell lung cancer （ NSCLC ）
Chemotherapy
Transforming growth factor （ TGF-β1 ）
Enzyme- linked immunoabsorbent assay （EliSA）
